Clark Capital Management Group’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Clark Capital Management Group’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.18M	Sell	32,929 -10,393	-24%	-$609K	0.01%	272
2026 Q1	$2.34M	Sell	43,322 -9,161	-17%	-$511K	0.01%	264
2025 Q4	$2.94M	Buy	52,483 +5,581	+12%	+$289K	0.02%	237
2025 Q3	$2.25M	Buy	+46,902	New	+$2.1M	0.01%	254
2022 Q3	–	Sell	-112,261	Closed	-$4.71M	–	385
2022 Q2	$4.71M	Buy	+112,261	New	+$4.71M	0.06%	166
2020 Q1	–	Sell	-41,097	Closed	-$1.88M	–	341
2019 Q4	$1.88M	Buy	+41,097	New	+$1.63M	0.04%	194

Other funds holding XPH

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

KWM

Kingsview Wealth Management Grants Pass, Oregon $8.25B AUM 24.8% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

FCBT

First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return

Envestnet Portfolio Solutions Chicago, Illinois $20.9B AUM 19.34% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Evelyn Partners London $46.9B AUM

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Clark Capital Management Group's XPH Position: Q2 2026 in Review

Clark Capital Management Group reduced its State Street SPDR S&P Pharmaceuticals ETF (XPH) stake by 24% in Q2 2026, selling an estimated $609K and leaving 32,929 shares worth $2.18M. The position accounts for 0.01% of the portfolio, ranked #272.

Clark Capital Management Group first reported a position in XPH in Q4 2019 and has held it in 6 quarters since. The position peaked at $4.71M in Q2 2022. 93 funds tracked by Wall St. Rank hold XPH as of Q2 2026.

Clark Capital Management Group held 32,929 shares of State Street SPDR S&P Pharmaceuticals ETF worth $2.18M as of Q2 2026.
Clark Capital Management Group sold 10,393 State Street SPDR S&P Pharmaceuticals ETF shares in Q2 2026, an estimated $609K.
State Street SPDR S&P Pharmaceuticals ETF made up 0.01% of Clark Capital Management Group's portfolio in Q2 2026, its #272 holding.
Clark Capital Management Group first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q4 2019 and has held it in 6 quarters since.
Clark Capital Management Group's State Street SPDR S&P Pharmaceuticals ETF position peaked at $4.71M in Q2 2022.
93 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q2 2026.

Based on Clark Capital Management Group's 13F filing for Q2 2026, filed 11 Aug 2026.